Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for the treatment of inherited retinal diseases and other retinal and refractive disorders.

Opus Genetics

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

Ocuphire Pharma, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 23, 2024 8:48 PM	44f6e316
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 23, 2024 8:48 PM	1d0a240e
crunchbase trigger	general	Nov 27, 2024 12:50 PM	7f71fe04
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 23, 2024 8:48 PM	77446587
news basic	general	Oct 23, 2024 8:48 PM	c82cfab8
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:OCUPHIRE

Opus Genetics

Last Close

1.33

23/10 20:00

Market Cap

42.77M

Beta: -

Volume Today

675.97K

Avg: -